Trovagene selects PRA Health Sciences to conduct Phase lb/ll trial of PCM-075 for AML

US-based biotechnology company Trovagene has chosen global contract research organisation (CRO) PRA Health Sciences to carry out its Phase lb/ll clinical trial of PCM-075, a polo-like kinase 1 (PLK1) inhibitor, to treat patients with acute myeloid le …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news